{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:17:48Z","timestamp":1786241868400,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["CER-2020C1-19212"],"award-info":[{"award-number":["CER-2020C1-19212"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR079822-01"],"award-info":[{"award-number":["R01AR079822-01"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012495","name":"Spondylitis Association of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The effectiveness of biologic therapies, primarily tumor necrosis factor inhibitors (TNFi), for children with spondyloarthritis (SpA) has made inactive disease a realistic patient outcome. However, biologic therapies are costly, primarily delivered by subcutaneous or intravenous route, and have non-trivial side effects. Many patients and families want to know if biologic medications can be discontinued after inactive disease is achieved. It remains unclear whether medication dose should remain unchanged, tapered (increase the time between doses), or discontinued once when inactive disease is attained.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The <jats:italic>B<\/jats:italic>iologic <jats:italic>A<\/jats:italic>batement and <jats:italic>C<\/jats:italic>apturing <jats:italic>K<\/jats:italic>ids\u2019 <jats:italic>O<\/jats:italic>utcomes and <jats:italic>F<\/jats:italic>lare <jats:italic>F<\/jats:italic>requency in <jats:italic>J<\/jats:italic>uvenile <jats:italic>SpA<\/jats:italic> (BACK-OFF JSpA) trial is a multicenter pragmatic trial that will randomize 198 participants ages 8\u201321 years old with SpA and sustained inactive disease on standard TNFi dosing to (1) continue standard TNFi dosing, (2) fixed longer dosing intervals of TNFi, or (3) stop TNFi. The trial will compare the hazard rate of protocol-defined flare and participants\u2019 emotional health among the 3 groups over 12 months. Innovative aspects of this trial are the involvement of patient and parent stakeholders in the design and conduct of the study as well as an electronic health record-based enhanced recruitment strategy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is the first randomized pragmatic trial to assess the efficacy of TNFi de-escalation strategies in children with JSpA with sustained inactive disease. This research will improve the evidence base that patients, caregivers, and rheumatologists use to make shared decisions about continued treatment versus de-escalation of TNFi therapy in this population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> NCT04891640. Registered on 18 May 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-07038-6","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T09:03:37Z","timestamp":1675847017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biologic Abatement and Capturing Kids\u2019 Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-0443","authenticated-orcid":false,"given":"Pamela F.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora E.","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Neu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kohlheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"issue":"8","key":"7038_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3899\/jrheum.090937","volume":"37","author":"V Kunjir","year":"2010","unstructured":"Kunjir V, Venugopalan A, Chopra A. Profile of Indian patients with juvenile onset chronic inflammatory joint disease using the ILAR classification criteria for JIA: a community-based cohort study. J Rheumatol. 2010;37(8):1756\u201362.","journal-title":"J Rheumatol"},{"issue":"4","key":"7038_CR2","first-page":"589","volume":"9","author":"AM Rosenberg","year":"1982","unstructured":"Rosenberg AM, Petty RE, Oen KG, Schroeder ML. Rheumatic diseases in Western Canadian Indian children. J Rheumatol. 1982;9(4):589\u201392.","journal-title":"J Rheumatol"},{"issue":"4","key":"7038_CR3","first-page":"783","volume":"25","author":"K Oen","year":"1998","unstructured":"Oen K, Schroeder M, Jacobson K, et al. Juvenile rheumatoid arthritis in a Canadian First Nations (aboriginal) population: onset subtypes and HLA associations. J Rheumatol. 1998;25(4):783\u201390.","journal-title":"J Rheumatol"},{"issue":"4","key":"7038_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jmii.2012.03.006","volume":"46","author":"CC Shen","year":"2013","unstructured":"Shen CC, Yeh KW, Ou LS, Yao TC, Chen LC, Huang JL. Clinical features of children with juvenile idiopathic arthritis using the ILAR classification criteria: a community-based cohort study in Taiwan. J Microbiol Immunol Infect. 2013;46(4):288\u201394.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"7038_CR5","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7038_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3899\/jrheum.150430","volume":"43","author":"T Constantin","year":"2016","unstructured":"Constantin T, Foeldvari I, Vojinovic J, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43(4):816\u201324.","journal-title":"J Rheumatol"},{"issue":"11","key":"7038_CR7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SM, Horneff G, et al. A Randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res. 2015;67(11):1503\u201312.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"7038_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3899\/jrheum.180456","volume":"46","author":"J Guzman","year":"2019","unstructured":"Guzman J, Henrey A, Loughin T, et al. Predicting which children with juvenile idiopathic arthritis will not attain early remission with conventional treatment: results from the ReACCh-Out cohort. J Rheumatol. 2019;46(6):628\u201335.","journal-title":"J Rheumatol"},{"issue":"4","key":"7038_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40801-016-0093-2","volume":"3","author":"T Gu","year":"2016","unstructured":"Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF. Comparing biologic cost per treated patient across indications among adult US managed care patients: a retrospective cohort study. Drugs Real World Outcomes. 2016;3(4):369\u201381.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"7038_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12969-016-0083-7","volume":"14","author":"P Livermore","year":"2016","unstructured":"Livermore P, Eleftheriou D, Wedderburn LR. The lived experience of juvenile idiopathic arthritis in young people receiving etanercept. Pediatr Rheumatol Online J. 2016;14(1):21.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"7038_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00431-017-2960-6","volume":"176","author":"F Vanoni","year":"2017","unstructured":"Vanoni F, Minoia F, Malattia C. Biologics in juvenile idiopathic arthritis: a narrative review. Eur J Pediatr. 2017;176(9):1147\u201353.","journal-title":"Eur J Pediatr"},{"issue":"5","key":"7038_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/BOR.0000000000000090","volume":"26","author":"ML Mannion","year":"2014","unstructured":"Mannion ML, Beukelman T. Risk of malignancy associated with biologic agents in pediatric rheumatic disease. Curr Opin Rheumatol. 2014;26(5):538\u201342.","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"7038_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2017-212613","volume":"77","author":"T Beukelman","year":"2018","unstructured":"Beukelman T, Xie F, Chen L, et al. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. 2018;77(7):1012\u20136.","journal-title":"Ann Rheum Dis"},{"key":"7038_CR14","unstructured":"Immunex Corporation. Enbrel (etanercept) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf. Revised December 2012. Accessed 16 Dec 2021."},{"key":"7038_CR15","unstructured":"Janssen Biotech, Inc. Remicade (infliximab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf. Revised November 2013. Accessed 16 Dec 2021."},{"key":"7038_CR16","unstructured":"AbbVie Inc. Humira (adalimumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf. Revised October 2018. Accessed 16 Dec 2021."},{"key":"7038_CR17","unstructured":"Janssen Biotech, Inc. Simponi (golimumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125289s0064lbl.pdf. Revised December 2011. Accessed 16 Dec 2021."},{"key":"7038_CR18","unstructured":"UCB, Inc. Cimzia (certolizumab pegol) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125160s270lbl.pdf. Revised January 2017. Accessed 16 Dec 2021."},{"issue":"7","key":"7038_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1136\/ard.2008.101030","volume":"68","author":"FH Prince","year":"2009","unstructured":"Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1228\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7038_CR20","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00296-012-2642-7","volume":"33","author":"Y Cai","year":"2013","unstructured":"Cai Y, Liu X, Zhang W, Xu J, Cao L. Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission. Rheumatol Int. 2013;33(9):2277\u201382.","journal-title":"Rheumatol Int"},{"issue":"3","key":"7038_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3899\/jrheum.161078","volume":"44","author":"DB Horton","year":"2017","unstructured":"Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic jia: a survey of the childhood arthritis and rheumatology research alliance. J Rheumatol. 2017;44(3):352\u201360.","journal-title":"J Rheumatol"},{"key":"7038_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jclinepi.2020.09.036","volume":"129","author":"CB Forrest","year":"2021","unstructured":"Forrest CB, McTigue KM, Hernandez AF, et al. PCORnet(R) 2020: current state, accomplishments, and future directions. J Clin Epidemiol. 2021;129:60\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"7038_CR23","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"2","key":"7038_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190\u20137.","journal-title":"J Rheumatol"},{"key":"7038_CR25","doi-asserted-by":"publisher","unstructured":"Weiss PF, Brandon TG, Ryan ME, et al. Development and validation of the juvenile spondyloarthritis disease flare (JSpAflare) measure: Ascertaining flare in patients with inactive disease. Arthritis Care Res (Hoboken). 2021:10.1002\/acr.24763. https:\/\/doi.org\/10.1002\/acr.24763.","DOI":"10.1002\/acr.24763"},{"issue":"7","key":"7038_CR26","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","volume":"79","author":"RB Landewe","year":"2020","unstructured":"Landewe RB, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 2020;79(7):920\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7038_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13063-019-4000-5","volume":"21","author":"CAJ Michielsens","year":"2020","unstructured":"Michielsens CAJ, Boers N, den Broeder N, et al. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. Trials. 2020;21(1):90.","journal-title":"Trials"},{"key":"7038_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13063-015-0828-5","volume":"16","author":"C Pontes","year":"2015","unstructured":"Pontes C, Gratacos J, Torres F, et al. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. Trials. 2015;16:370.","journal-title":"Trials"},{"issue":"10086","key":"7038_CR29","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316.","journal-title":"Lancet"},{"issue":"1","key":"7038_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","volume":"21","author":"J Gratacos","year":"2019","unstructured":"Gratacos J, Pontes C, Juanola X, et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):11.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"7038_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):163\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"7038_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D'Agostino Sr","year":"2003","unstructured":"D\u2019Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22(2):169\u201386.","journal-title":"Stat Med"},{"key":"7038_CR33","doi-asserted-by":"publisher","unstructured":"Neu E, Sears C, Brandon T, et al. Stakeholder outcome prioritization in the Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK\u2010OFF JSpA) trial. Health Expect. 2022;1\u20107. https:\/\/doi.org\/10.1111\/hex.13655.","DOI":"10.1111\/hex.13655"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-07038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-07038-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-07038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T09:08:17Z","timestamp":1675847297000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-07038-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7038"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-07038-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study\u2019s protocol was reviewed and approved by the Children\u2019s Hospital of Philadelphia\u2019s (IRB 21-018442) Committees of the Protection of Human Subjects on 6\/1\/2021. Written informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"Drs. Weiss and Lovell consult for pharmaceutical companies but this consulting work is not related to the PCORI-funded project.Dr. Weiss: Lily, Biogen, Pfizer, Inc., and NovartisDr. Lovel: United BioSource Corporation, Hoffman-LaRoche, Inc., Janssen Research & Development, LLC, Bristol -Myers Squibb, AstraZeneca, Pfizer, Inc., AbbVie Inc., GlaxoSmithKline, Novartis Pharmaceuticals, Abbott Laboratories, and Roche Laboratories, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"100"}}